London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I concur, lots of valuable information cascaded by Laura and Kid.
Made investing here a lot easier.
Thank you
Acker
Already at 3p! No need for patience
Offer is printed at 3p
Oh wow!! 3p we are knocking on your door already!
Your work Laura and Kid is a credit to the board and partly the reason I bought in last week. I was able to find a lot of the info I needed through various links posted!
+25% 3p looming
I have been fortunate (and patient ) to make 200%+ on another share (pos) so added more here and FCS last week
Kidlington etc have been here longer and know their stuff
Please move on as you know nothing and sold last week
Often deals are client confidential but £1.5mln of deals clearly stated in previous RNS
Can sell but NT to buy
Only downside orders with no value shown in Rns ,or their idea of a large order is £125,000 .
Off to a flying start and looks like we're in for a good day. Could it be the 300% day that kickstarted the last mega rise?
Wow +20%
Hepran
PYC has won 4-6 contracts already since the start of the next financial year (July 2023 onwards )and has a pipeline of £1.5mln + we now have Merck resuming with us (annually spend £500k with PYC ) ,
Therefore £8mln cap would still only be about 4 x potential revenues (and that's without any block buster news /partnerships such as the potential £6mln from VAL201)
Morning all! Some great finds on our new man Pistol
Pete! Let’s see where we end up today but expect it to start with a 3.
So it’s safe to assume that with double the shares in issue now, a mcap between £8-10m is achievable which is approx 4x from the current position
I'm not expecting PYC to go to 30p+ intraday (although that would be very nice!). But a rise over the next few sessions to 10p if we get more news is a distinct possibility. Next stop today is 3.5-4p if the momentum continues. If we achieve 4p shortly then 10p is inbound with news....
Good luck, Brighty
Peter can be also heard here on a podcast in 2022? When he was head of BD at NIHR
https://www.theendpointpodcast.com/podcasts/blog-post-title-one-jtemk-e2F1Y-w7ran
Brighty they had 57m at 30p = £17m mcap!
Brighty thanks for me it's always the relevant mcap that counts as number of shares will have changed. Can you work out that mcap when the shares hit those prices?
Tia
Peter Sargent has come from Syneos health.
In March they signed a collaboration with Microsoft to accelerate AI.
https://www.investor.syneoshealth.com/news-releases/news-release-details/syneos-health-collaborates-microsoft-accelerate-ai-across
Syneos are also about to be taken private for $7B
https://www.investor.syneoshealth.com/news-releases/news-release-details/syneos-health-be-acquired-private-investment-consortium
You are very welcome,Kidlington is a very informative poster on here
L
Yes it was Nov 27th 2017 to Nov 30th 2017 below when the big PYC gains happened (& a few days pre and post). Here's the PYC chart covering that specific period from 1.3p to 30p in just a few days....
Date Open High Low Close Vol
Nov 30, 2017 10.51 32.00 9.50 17.125 49,900,790
Nov 29, 2017 5.00 10.00 3.77 9.50 78,119,582
Nov 28, 2017 1.30 4.2659 1.235 4.25 102,217,619
We know that the PYC share price can motor. It's done it before....
Good luck, Brighty
Great posts thank you to l and k
AI has also been found to be useful for increasing the chances of a new medicine being successful in treating patients
From PYC website regarding PYC A.I applications
Personalised Dosing Tool Development
Data Identification
Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria
AI & Machine Learning
Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy
Web-Based Tool
Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients
Good morning Andy
Personalised medicine is what PYC do ànd is what their dosing tool does (see Januarry 2023 RNS)
They have an A.i/ machine learning dosing tool and the FDA are warning drug conapnies to use these tools if they want to have FDA clearnec e,it is FDA guidelines called Project Optimus
pyc published their findings at the April 2023 AACR and also have their work published in the world famous Frontiers magazine
See below the RNS about about it from April_May 2023
Project Optimus has relevance to Physiomics both in its core consulting business and its personalised oncology initiatives. In core consulting, Project Optimus encourages and some would say even mandates biotech and pharma companies to fully utilise all available non-clinical and clinical data to make informed decisions about clinical trial design and biologically effective dose. The Company believes that there is an increasing expectation that companies meeting with the FDA should have utilised mathematical modelling in support of clinical trial design and dosing decision making. The Company has first hand experience of this through the translational modelling work it has completed for multiple small and medium sized clients in recent years.
Looking beyond drug development, the Company sees a clear implication of Project Optimus on dosing of approved drugs in cancer. The vast majority of cancer drugs are still approved on a "one size fits all" basis with, at most, adjustments in dosing being made to account for body weight or surface area of individual patients. The Company believes that the future direction of cancer drug dosing will take into account its effect in each individual and we believe that our personalised dosing tool is a clear step towards achieving that goa